A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617.
Description:
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT05633160 - Click here to see study onClinicalTrials.gov
- • Eastern Cooperative Oncology Group performance status of 0 to 2
- •≥1 Metastatic lesion that is present at screening
- • Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)
- • Have progressive metastatic castration-resistant prostate cancer (mCRPC)
- • Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa)
- • Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings
- • Prior history of leukemia or Myelodysplastic Syndrome
- • Histologic diagnosis of small cell prostate cancer
- • Symptomatic Brain metastasis
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
17607 Gold Plaza, Omaha, Nebraska 68130, United States
Durham, North Carolina 27710, United States
Grand Rapids, Michigan 49503, United States
Principal Investigator
Brandon Mancini, MD
Miami, Florida 33165, United States
Principal Investigator
Frankis Almaguel, MD
Stanford, California 94305, United States
Principal Investigator
Hong Song, MD, Ph.D.
Houston, Texas 77030, United States
Principal Investigator
Amado Zurita-Saavedra, MD
